

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/207823 A1

(51) International Patent Classification:

C07K 14/47 (2006.01) C07K 7/06 (2006.01)
A61K 39/00 (2006.01) C07K 7/08 (2006.01)
A61K 9/127 (2006.01) C12N 15/12 (2006.01)
A61P 35/00 (2006.01) C12N 15/87 (2006.01)
A61P 37/04 (2006.01) C12N 5/071 (2010.01)
C07K 14/725 (2006.01) C12N 5/10 (2006.01)
C07K 14/74 (2006.01)

(21) International Application Number:

PCT/CA2021/050340

(22) International Filing Date:

15 March 2021 (15.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/009,853 14 April 2020 (14.04.2020) US

(71) Applicant: UNIVERSITÉ DE MONTRÉAL [CA/CA];
2900, boulevard Édouard-Montpetit, Montréal, Québec
H3T 1J4 (CA).

(72) Inventors: PERREAULT, Claude; 70, avenue Claude-
Champagne, Montréal, Québec H2V 2X1 (CA).
THIBAUT, Pierre; 8560, rue Joseph Quintal, Montre-
al, Québec H2M 2M8 (CA). LEMIEUX, Sébastien; 271,
rue du Fort-Remy, Lasalle, Québec H8R 4C6 (CA). EHX,
Grégory; 440, rue De La Gauchetière Est, Appartement
210, Montréal, Québec H2L 2M5 (CA). HARDY, Marie-

Pierre; 618, rue de Bétusy, Terrebonne, Québec J6Y 0A5
(CA).

(74) Agent: LAVERY, DE BILLY, LLP; 1, Place Ville Marie,
Bureau 4000, Montréal, Québec H3B 4M4 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(54) Title: NOVEL TUMOR-SPECIFIC ANTIGENS FOR ACUTE MYELOID LEUKEMIA (AML) AND USES THEREOF




FIG. 5A

(57) Abstract: Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of leukemia such as AML is also described.

[Continued on next page]



WO 2021/207823 A1

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*